[3] Institute BCN Safety Profile The safety profile of any Institute BCN product depends on the specific formulation, treatment area, route of administration, practitioner technique, and patient factors
Thermo Fisher
Expecting reasonable, gradual progress rather than immediate transformation leads to better adherence and more sustainable results
The pregnancy and delivery had been normal and there was no history of medication during pregnancy
Front Immunol (2021) 12:764825
Extra caution is advised in people with: A history of pancreatitis Severe acidity or gastroparesis (very slow stomach emptying) Known gallstones or gallbladder disease Advanced kidney disease Significant diabetic eye disease (retinopathy) A very low BMI or a history of eating disorders Pregnancy, plans to become pregnant, or breastfeeding, since some GLP-1 medicines stay in the body for several weeks after stopping Significant depression, who should be monitored carefully Upcoming surgery, endoscopy, or a procedure needing anaesthesia or sedation, since delayed stomach emptying can raise aspiration risk and temporary stopping may be advised How GLP-1 side effects usually progress: a typical timeline Every person is different, but clinical practice and studies suggest a rough pattern [6]: First 2 to 6 weeks: nausea, early fullness, and constipation are most common